Cutaneous Leishmaniasis

1 million new cases globally, annually.

The leishmaniases are a group of diseases caused by the parasite Leishmania

An Orphan condition with unmet needs

A Gates Foundation priority NTD (neglected tropical disease)

WHO rare disease division coordinating global effort to treat and eradicate.

FDA – Orphan Drug designated.

Immigration has

migrated the parasite into

North America and Europe.

The 10 countries with the highest cases reported in 2015 are: Afghanistan, Algeria, Brazil, Colombia, Iran, Iraq, Peru, the Syrian Arab Republic, Tunisia and Yemen.

Formulation by Nextar Chemipharma, Israel

Excellent medical research team headed by Dr. Daniela Kamir, Phd microbiology, Yale University.

Successful Bio-essay’s on human macrophages, 100% success, conducted by Professor Charles Jaffe, Hebrew University at Hadassah Medical Center, Jerusalem.

Clinical Program planed at La Rabta Hospital, Tunis along with Professor Mourad Mokni, a world renown expert on C. Leishmaniasis and endorsed by the Head of NTD at the WHO.

C. Leishmaniasis has no known cure, it afflicts nearly 1 million new patients every year, mostly in the Levant and North Africa. Over 10 million persons afflicted world-wide.

Market Potential approximately $60,000,000 annually for new patients,  Fast tracked Orphan Condition.

Re-formulation/Re-purposing variations can include: V. Leishmaniasis, M. Leishmaniasis, Canine Leishmaniasis and Chronic Wounds.Breakthrough Therapies